Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2007
Breast cancer in the elderlyDiana Crivellari, Matti Aapro, Robert Leonard, et al.
Radiology and Oncology|March 2, 2013
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studiesAlessandro Tuzi, Davide Lombardi, Diana Crivellari, et al.
Tumori|August 19, 2004
Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional studyDavide Lombardi, Diana Crivellari, Cristina Scuderi, et al.
BMC Cancer|June 13, 2006
Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of ItalyGianMaria Miolo, Lara Della Puppa, Manuela Santarosa, et al.
BMC Cancer|October 13, 2009
Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancersGianMaria Miolo, Vincenzo Canzonieri, Clelia De Giacomi, et al.
Archives of Gynecology and Obstetrics|July 8, 2011
Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?Gianmaria Miolo, Ettore Bidoli, Davide Lombardi, et al.
Tumori|April 13, 2012
Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experienceDiana Crivellari, Simon Spazzapan, Davide Lombardi, et al.
Critical Reviews in Oncology/Hematology|January 20, 2012
Target therapy in elderly breast cancer patientsPaolo Carli, Elisa Turchet, Daniela Quitadamo, et al.
Tumori|February 12, 2004
Acceptance of external infusion pumps in patients with advanced breast cancer receiving continuous infusion fluorouracilDavide Lombardi, Vincenzo Di Lauro, Barbara Piani, et al.
Cancer Treatment Reviews|January 17, 2013
Targeting triple negative breast cancer: is p53 the answer?Natalie Turner, Erica Moretti, Olimpia Siclari, et al.
Pageof 4